ROQ vs. OBD, BVX, IXI, HEMO, FAB, CIZ, APTA, GENF, EVG, and MTFB
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include Oxford BioDynamics (OBD), BiVictriX Therapeutics (BVX), IXICO (IXI), Hemogenyx Pharmaceuticals (HEMO), Fusion Antibodies (FAB), Cizzle Biotechnology (CIZ), Aptamer Group (APTA), Genflow Biosciences (GENF), Evgen Pharma (EVG), and Motif Bio (MTFB). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs.
Oxford BioDynamics (LON:OBD) and Roquefort Therapeutics (LON:ROQ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability.
Roquefort Therapeutics has lower revenue, but higher earnings than Oxford BioDynamics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.
Oxford BioDynamics has a net margin of -1,800.32% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -29.57% beat Oxford BioDynamics' return on equity.
44.3% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 1.7% of Roquefort Therapeutics shares are owned by institutional investors. 16.8% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 60.4% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Oxford BioDynamics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500.
In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.
Oxford BioDynamics received 104 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users.
Summary
Oxford BioDynamics and Roquefort Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 3/30/2025 by MarketBeat.com Staff
Buy ROQ Stock Free ROQ Stock Alerts